<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Purinergic Signal</journal-id>
      <journal-title>Purinergic Signalling</journal-title>
      <issn pub-type="ppub">1573-9538</issn>
      <issn pub-type="epub">1573-9546</issn>
      <publisher>
        <publisher-name>Springer Netherlands</publisher-name>
        <publisher-loc>Dordrecht</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">18404447</article-id>
      <article-id pub-id-type="pmc">2072915</article-id>
      <article-id pub-id-type="publisher-id">9068</article-id>
      <article-id pub-id-type="doi">10.1007/s11302-007-9068-9</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Paper</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>New 2,6,9-trisubstituted adenines as adenosine receptor antagonists: a preliminary SAR profile</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lambertucci</surname>
            <given-names>Catia</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cristalli</surname>
            <given-names>Gloria</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Dal Ben</surname>
            <given-names>Diego</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kachare</surname>
            <given-names>Dhuldeo D.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bolcato</surname>
            <given-names>Chiara</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Klotz</surname>
            <given-names>Karl-Norbert</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name name-style="western">
            <surname>Spalluto</surname>
            <given-names>Giampiero</given-names>
          </name>
          <address>
            <phone>+39-040-5583726</phone>
            <fax>+39-040-52572</fax>
            <email>spalluto@units.it</email>
          </address>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name name-style="western">
            <surname>Volpini</surname>
            <given-names>Rosaria</given-names>
          </name>
          <address>
            <phone>+39-0737-402278</phone>
            <fax>+39-0737-402295</fax>
            <email>rosaria.volpini@unicam.it</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Department of Chemical Sciences, University of Camerino, 62032 Camerino, Italy </aff>
        <aff id="Aff2"><label>2</label>Department of Pharmaceutical Sciences, University of Trieste, 34127 Trieste, Italy </aff>
        <aff id="Aff3"><label>3</label>Institut f&#xFC;r Pharmakologie und Toxikologie, Universit&#xE4;t W&#xFC;rzburg, 97078 W&#xFC;rzburg, Germany </aff>
        <aff id="Aff4"><label>4</label>Dipartimento di Scienze Farmaceutiche, p.le Europa, 1, 34127 Trieste, Italy </aff>
        <aff id="Aff5"><label>5</label>Dipartimento di Scienze Chimiche, via S. Agostino, 1, 62032 Camerino, Italy </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>19</day>
        <month>9</month>
        <year>2007</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>9</month>
        <year>2007</year>
      </pub-date>
      <volume>3</volume>
      <issue>4</issue>
      <fpage>339</fpage>
      <lpage>346</lpage>
      <history>
        <date date-type="received">
          <day>20</day>
          <month>7</month>
          <year>2007</year>
        </date>
        <date date-type="accepted">
          <day>31</day>
          <month>7</month>
          <year>2007</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Springer Science + Business Media B.V. 2007</copyright-statement>
      </permissions>
      <abstract>
        <p>A new series of 2,6,9-trisubstituted adenines (<bold>5&#x2013;14</bold>) have been prepared and evaluated in radioligand binding studies for their affinity at the human A<sub>1</sub>, A<sub>2A</sub> and A<sub>3</sub> adenosine receptors and in adenylyl cyclase experiments for their potency at the human A<sub>2B</sub> subtype. From this preliminary study the conclusion can be drawn that introduction of bulky chains at the <italic>N</italic><sup>6</sup> position of 9-propyladenine significantly increased binding affinity at the human A<sub>1</sub> and A<sub>3</sub> adenosine receptors, while the presence of a chlorine atom at the 2 position resulted in a not univocal effect, depending on the receptor subtype and/or on the substituent present in the <italic>N</italic><sup>6</sup> position. However, in all cases, the presence in the 2 position of a chlorine atom favoured the interaction with the A<sub>2A</sub> subtype. These results demonstrated that, although the synthesized compounds were found to be quite inactive at the human A<sub>2B</sub> subtype, adenine is a useful template for further development of simplified adenosine receptor antagonists with distinct receptor selectivity profiles.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Adenine derivatives</kwd>
        <kwd>Adenosine receptors</kwd>
        <kwd>Adenosine receptor antagonists</kwd>
        <kwd>Adenosine receptor ligands</kwd>
        <kwd>G protein-coupled receptors</kwd>
      </kwd-group>
      <custom-meta-wrap>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer Science+Business Media B.V. 2007</meta-value>
        </custom-meta>
      </custom-meta-wrap>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p>Adenosine, a naturally occurring nucleoside, is involved in a wide variety of physiological and pathophysiological processes [<xref ref-type="bibr" rid="CR1">1</xref>]. Adenosine mediates these effects through the activation of at least four human receptor subtypes (P1), belonging to the superfamily of G protein-coupled receptors, which have been recently cloned [<xref ref-type="bibr" rid="CR2">2</xref>] and classified as A<sub>1</sub>, A<sub>2A</sub>, A<sub>2B</sub> and A<sub>3</sub> [<xref ref-type="bibr" rid="CR3">3</xref>]. The subtypes are classified on the bases of coupling to second messengers and pharmacological profiles for agonists and antagonists. In fact, A<sub>1</sub> and A<sub>3</sub> adenosine receptor subtypes are linked to inhibition of adenylyl cyclase and A<sub>2A</sub> and A<sub>2B</sub> subtypes are linked to stimulation of the same enzyme [<xref ref-type="bibr" rid="CR4">4</xref>].</p>
      <p>In particular, A<sub>2B</sub> receptors have been implicated in several physiological functions such as the regulation of mast cell secretion [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>], gene expression [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>], cell growth [<xref ref-type="bibr" rid="CR9">9</xref>] and intestinal functions. A<sub>2B</sub> receptors may also play a role in asthma, since they mediate mast cell degranulation from human mast cells and are present in high density in human blood eosinophils [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. For this reason A<sub>2B</sub> antagonists could be considered potential antiasthmatic agents [<xref ref-type="bibr" rid="CR10">10</xref>&#x2013;<xref ref-type="bibr" rid="CR12">12</xref>]. While the A<sub>1</sub>, A<sub>2A</sub> and A<sub>3</sub> adenosine receptors have been pharmacologically characterized through the use of highly potent and selective agonists and/or antagonists, an accurate investigation of the pathophysiological role of A<sub>2B</sub> receptors is precluded due to the lack of very selective ligands [<xref ref-type="bibr" rid="CR13">13</xref>]. On the other hand, only recently radiolabelled adenosine antagonists have been used for binding assays at the A<sub>2B</sub> receptor subtype [<xref ref-type="bibr" rid="CR1">1</xref>]. Recently, xanthine derivatives, such as compounds <bold>1</bold> and <bold>2</bold> in Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>, have been proposed as potent and selective adenosine receptor antagonists [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. On the other hand, in the non-xanthine family poor results have been obtained in recent years. However, mention should be made of the pyrazolo-triazolo-pyrimidine derivative <bold>3</bold>, which showed promising binding affinity at the A<sub>2B</sub> adenosine receptor although the level of selectivity vs the human (h) A<sub>3</sub> subtype was still poor [<xref ref-type="bibr" rid="CR16">16</xref>]. Very recently, a bipyrimidyl derivative <bold>4</bold> has been proposed as an A<sub>2B</sub> adenosine receptor antagonist, with affinity in the same range of compound <bold>3,</bold> while the selectivity vs the other receptor subtypes was found to be significantly better [<xref ref-type="bibr" rid="CR17">17</xref>] (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>).
<fig id="Fig1"><label>Fig.&#xA0;1</label><caption><p>Structures and binding profile (K<sub>i</sub> nM) of some A<sub>2B</sub> adenosine receptor antagonists</p></caption><graphic position="anchor" xlink:href="11302_2007_9068_Fig1_HTML" id="MO1"/></fig></p>
      <p>A structural analysis of the derivatives <bold>1</bold> and <bold>3</bold> clearly shows the presence of bulky substituents such as aryloxyacetylamino-phenyl groups at the 8 position (compound <bold>1</bold>) and arylacetyl moiety at the N5 position (compound <bold>3</bold>).</p>
      <p>On the other hand, in recent years a number of substituted adenines have been synthesized and tested at the four adenosine receptor subtypes, demonstrating that the introduction of different substituents at the 2, 8 and 9 positions of the adenine core resulted in high-affinity antagonists with distinct receptor selectivity profile [<xref ref-type="bibr" rid="CR18">18</xref>&#x2013;<xref ref-type="bibr" rid="CR22">22</xref>]. At the A<sub>2B</sub> receptor the derivatives bearing an ethyl in the 9 position and linear chains in the 2 position showed potency in the &#x3BC;M range, while the presence of sterically hindered substituents in the same positions was detrimental for the potency. Furthermore, substitution of the 9-ethyl group with a propyl chain seems to favour the interaction with human A<sub>2B</sub> receptors [<xref ref-type="bibr" rid="CR21">21</xref>].</p>
      <p>Hence, on the basis of the results obtained with compound <bold>3</bold>, introduction of a bulky substituent on the <italic>N</italic><sup>6</sup> amino group of the adenine and 2-chloroadenine moiety could increase potency and selectivity for the human A<sub>2B</sub> adenosine receptor subtypes.</p>
      <p>Hence, bulky substituents such as arylacetyl or aryloxyphenylacetyl moieties were introduced on the <italic>N</italic><sup>6</sup> amino group of compounds <bold>5</bold> and <bold>6</bold> to obtain derivatives <bold>7</bold>&#x2013;<bold>14</bold>, with the aim of finding a new class of A<sub>2B</sub> antagonists (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>).
<fig id="Fig2"><label>Fig.&#xA0;2</label><caption><p>Structures of designed compounds</p></caption><graphic position="anchor" xlink:href="11302_2007_9068_Fig2_HTML" id="MO2"/></fig></p>
    </sec>
    <sec id="Sec2">
      <title>Chemistry</title>
      <p>The designed compounds (<bold>5&#x2013;14</bold>) have been synthesized as summarized in Schemes&#xA0;<xref rid="Sch1" ref-type="fig">1</xref> and <xref rid="Sch2" ref-type="fig">2</xref>. The starting 9-propyladenine (<bold>5</bold>) [<xref ref-type="bibr" rid="CR23">23</xref>] was obtained by alkylation of commercially available adenine (<bold>15</bold>) with propyliodide in the presence of potassium carbonate. Flash chromatography led to the desired 9-substituted isomer <bold>5</bold> as the major product (yield 79%) together with the 7-isomer <bold>5a</bold> (yield 9%). Isomeric structure of compounds <bold>5</bold> and <bold>5a</bold> was assigned on the bases of 1D-<sup>1</sup>H-NOE difference spectra. In fact, irradiation of both CH<sub>2</sub> groups of the propylic chain in compound <bold>5a</bold> gave a NOE at both H-C(8) and 6-NH<sub>2</sub> groups, demonstrating the 7 position as the alkylation site. On the contrary, a NOE at both H-C(8) and H-C(2), and not at the 6-NH<sub>2</sub> group in compound <bold>5</bold>, upon saturation of CH<sub>2</sub> groups of the propylic chain, confirmed the 9 position as the alkylation site.
<fig id="Sch1"><label>Scheme&#xA0;1</label><caption><p><bold>a</bold> Synthesis of 9-propyladenine; <bold>b</bold> Synthesis of 2-chloro-9-propyladenine. Reagents: i: DMF, K<sub>2</sub> CO<sub>3</sub>, propyliodide, RT; ii: liq. NH<sub>3</sub>, sealed tube, RT</p></caption><graphic position="anchor" xlink:href="11302_2007_9068_Sch1_HTML" id="MO3"/></fig><fig id="Sch2"><label>Scheme&#xA0;2</label><caption><p>Reagents: i: CDI, dry THF, reflux</p></caption><graphic position="anchor" xlink:href="11302_2007_9068_Sch2_HTML" id="MO4"/></fig></p>
      <p>The 2-chloro derivative <bold>6</bold> was obtained by alkylation of commercially available 2,6-dichloropurine (<bold>16</bold>) with propyliodide, using the same procedure utilized for compound <bold>5</bold>, to afford the 9-substituted isomer <bold>17</bold> as the major product (yield 75%) along with the 7-isomer <bold>17a</bold> (yield 10%) [<xref ref-type="bibr" rid="CR24">24</xref>]. [<sup>1</sup>H]-NMR spectra of <bold>17</bold> and <bold>17a</bold> in CDCl<sub>3</sub> are in agreement with those reported in the literature [<xref ref-type="bibr" rid="CR24">24</xref>]; in the experimental part [<sup>1</sup>H]-NMR spectra of the same compounds are reported using dimethyl sulfoxide (DMSO) as the solvent. Compound <bold>17</bold> was reacted with liquid ammonia in a sealed tube at room temperature (RT) overnight to give the 2-chloro-9-propyladenine (<bold>6</bold>) [<xref ref-type="bibr" rid="CR24">24</xref>] (Scheme&#xA0;<xref rid="Sch1" ref-type="fig">1</xref>).</p>
      <p>Final compounds <bold>7&#x2013;14</bold> were obtained by condensation of amino compounds <bold>5</bold> or <bold>6</bold> with the appropriate acid <bold>18&#x2013;22</bold> [<xref ref-type="bibr" rid="CR25">25</xref>] in the presence of carbonyldiimidazole in tetrahydrofurane (THF) at reflux for 18&#xA0;h (Scheme&#xA0;<xref rid="Sch2" ref-type="fig">2</xref>).</p>
    </sec>
    <sec id="Sec3">
      <title>Results and discussion</title>
      <p>All the compounds were evaluated at the human recombinant adenosine receptors, stably transfected into Chinese hamster ovary (CHO) cells, utilizing radioligand binding studies (A<sub>1</sub>, A<sub>2A</sub>, A<sub>3</sub>) or adenylyl cyclase activity assay (A<sub>2B</sub>). Receptor binding affinity was determined using [<sup>3</sup>H]CCPA (2-chloro-<italic>N</italic><sup>6</sup>-cyclopentyladenosine) as the radioligand for A<sub>1</sub> receptors, whereas [<sup>3</sup>H]NECA (5&#x2019;-<italic>N</italic>-ethylcarboxamidoadenosine) was used for the A<sub>2A</sub> and A<sub>3</sub> subtypes. In the case of A<sub>2B</sub> receptors K<sub>i</sub> values were calculated from IC<sub>50</sub> values determined by inhibition of NECA-stimulated adenylyl cyclase activity. K<sub>i</sub> values are in &#x3BC;M, with 95% confidence intervals in parentheses [<xref ref-type="bibr" rid="CR26">26</xref>]. The results of binding and cyclase activity studies are reported in Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>.
<table-wrap id="Tab1"><label>Table&#xA0;1</label><caption><p>Biological profile of synthesized compounds <bold>5&#x2013;14</bold></p></caption><graphic xlink:href="11302_2007_9068_Tab1_HTML" id="MO5"/><table-wrap-foot><p><sup>a</sup>Displacement of specific [<sup>3</sup>H]-CCPA binding at human A<sub>1</sub> receptors expressed in CHO cells. <sup>b</sup>Displacement of specific [<sup>3</sup>H]-NECA binding at human A<sub>2A</sub> receptors expressed in CHO cells. <sup>c</sup>K<sub>i</sub> values of the inhibition of NECA-stimulated adenylyl cyclase activity in CHO cells expressing human A<sub>2B</sub> receptors. <sup>d</sup>Displacement of specific [<sup>3</sup>H]-NECA binding at human A<sub>3</sub> receptors expressed in CHO cells.</p></table-wrap-foot></table-wrap></p>
      <p>All the tested compounds <bold>5&#x2013;14</bold> showed affinities at the human A<sub>1</sub>, A<sub>2A</sub> and A<sub>3</sub> adenosine receptors in the &#x3BC;M range without significant levels of selectivity. At A<sub>2B</sub> receptors most compounds were found to be inactive when tested at a concentration up to 100&#xA0;&#x3BC;M (K<sub>i</sub> values &gt; 30&#xA0;&#x3BC;M). It is quite evident that the introduction of phenylacetic or aryloxyphenylacetic moieties at the <italic>N</italic><sup>6</sup> position of 9-propyladenine (<bold>5</bold>) or of 2-chloro-9-propyladenine (<bold>6</bold>) to give compounds <bold>7&#x2013;14</bold> modifies the binding profile of the derivatives, although without significantly increasing binding affinity (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). On the other hand, the same substitutions were found to be detrimental for the activity at the A<sub>2B</sub> receptor subtype. In fact, the <italic>N</italic><sup>6</sup>-unsubstituted derivative <bold>6</bold> proved to be the most potent of the series with K<sub>i</sub> A<sub>2B</sub>&#x2009;=&#x2009;11&#xA0;&#x3BC;M.</p>
      <p>The effect of the chlorine at the 2 position on binding affinity at the adenosine receptors it is not univocal, depending on the receptor subtype and/or on the substituent in <italic>N</italic><sup>6</sup>. Analysis of the binding profile of the <italic>N</italic><sup>6</sup>-unsubstituted derivatives in more detail revealed that the presence of a chlorine atom at the 2 position (compound <bold>6</bold>) increased the affinity (A<sub>1</sub>, A<sub>2A</sub> and A<sub>3</sub>) and potency (A<sub>2B</sub>) at adenosine receptors two- to threefold compared with the unsubstituted analogue <bold>5</bold>.</p>
      <p>A quite similar profile could be observed when a 4-bromophenylacetic group was introduced at the <italic>N</italic><sup>6</sup> position (compare compound <bold>8</bold> with <bold>7</bold>).</p>
      <p>An opposite effect of the chlorine atom was detected at A<sub>1</sub>, A<sub>2B</sub> and A<sub>3</sub> receptors when a bulkier substituent, such as the 4-aryloxyphenylacetic chain, was introduced at the <italic>N</italic><sup>6</sup> position. In fact, this kind of combination significantly reduced or did not modify the A<sub>1</sub> and A<sub>3</sub> affinity and the A<sub>2B</sub> potency (<bold>9</bold>: K<sub>i</sub> A<sub>1</sub>&#x2009;=&#x2009;1.4&#xA0;&#x3BC;M, K<sub>i</sub> A<sub>2B</sub> &gt; 30&#xA0;&#x3BC;M, K<sub>i</sub> A<sub>3</sub>&#x2009;=&#x2009;5.3&#xA0;&#x3BC;M vs <bold>10</bold>: K<sub>i</sub> A<sub>1</sub>&#x2009;=&#x2009;26&#xA0;&#x3BC;M, K<sub>i</sub> A<sub>2B</sub>&#x2009;&gt;&#x2009;30&#xA0;&#x3BC;M, K<sub>i</sub> A<sub>3</sub>&#x2009;=&#x2009;4.9&#xA0;&#x3BC;M and <bold>12</bold>: K<sub>i</sub> A<sub>1</sub>&#x2009;=&#x2009;13&#xA0;&#x3BC;M, K<sub>i</sub> A<sub>2B</sub>&#x2009;=&#x2009;22&#xA0;&#x3BC;M, K<sub>i</sub> A<sub>3</sub>&#x2009;=&#x2009;10&#xA0;&#x3BC;M vs <bold>13</bold>: K<sub>i</sub> A<sub>1</sub>&#x2009;=&#x2009;22&#xA0;&#x3BC;M, K<sub>i</sub> A<sub>2B</sub>&#x2009;&gt;&#x2009;30&#xA0;&#x3BC;M, K<sub>i</sub> A<sub>3</sub>&#x2009;=&#x2009;19&#xA0;&#x3BC;M).</p>
      <p>However, in all cases, the presence of a chlorine atom in the 2 position favoured the interaction with the A<sub>2A</sub> subtype (compare A<sub>2A</sub> affinity of <bold>5</bold>, <bold>7</bold>, <bold>9</bold> and <bold>12</bold> with <bold>6</bold>, <bold>8</bold>, <bold>10</bold> and <bold>13</bold>, respectively), while the presence of any substituent on the <italic>N</italic><sup>6</sup> position seems to somewhat reduce the affinity. In fact the compound endowed with the highest A<sub>2A</sub> affinity proved to be the 2-chloro-9-propyladenine (<bold>6</bold>: K<sub>i</sub> A<sub>2A</sub>&#x2009;=&#x2009;2.2&#xA0;&#x3BC;M). These findings are in agreement with previous observations related to adenosine analogues strongly suggesting that the introduction of substituents in the <italic>N</italic><sup>6</sup> position dramatically reduces the A<sub>2A</sub> affinity [<xref ref-type="bibr" rid="CR27">27</xref>&#x2013;<xref ref-type="bibr" rid="CR32">32</xref>].</p>
      <p>Nevertheless, it should be underlined that the presence of a bulky chain at the <italic>N</italic><sup>6</sup> position significantly increased (20- to 70-fold) the affinity at the A<sub>1</sub> and A<sub>3</sub> subtypes in comparison with 9-propyladenine (<bold>9</bold>: K<sub>i</sub> A<sub>1</sub>&#x2009;=&#x2009;1.4&#xA0;&#x3BC;M and <bold>11</bold>: K<sub>i</sub> A<sub>3</sub>&#x2009;=&#x2009;1.4&#xA0;&#x3BC;M vs <bold>5</bold>: K<sub>i</sub> A<sub>1</sub>&#x2009;=&#x2009;24&#xA0;&#x3BC;M and K<sub>i</sub> A<sub>3</sub>&#x2009;&gt;&#x2009;100&#xA0;&#x3BC;M).</p>
      <p>This increase of affinity seems also to be modulated by the substituent on the aryloxyphenylacetic group; in fact, substitution with a lipophilic bromine (<bold>9</bold>) or methyl group (<bold>11</bold>) at the <italic>para</italic> position is responsible for the increased A<sub>1</sub> and A<sub>3</sub> receptor affinity, respectively, while the presence of a hydrogen (<bold>12</bold>) or a methoxy group (<bold>14</bold>) did not positively influence the binding profile.</p>
    </sec>
    <sec id="Sec4" sec-type="conclusion">
      <title>Conclusions</title>
      <p>In conclusion the study herein presented, although it did not reach the proposed goal of obtaining A<sub>2B</sub> adenosine receptor antagonists, increased knowledge of the structure-activity relationships in adenine derivatives.</p>
      <p>Moreover, it was demonstrated that the introduction of bulky substituents at the <italic>N</italic><sup>6</sup> position of adenine derivatives significantly increased the affinity at the A<sub>1</sub> and A<sub>3</sub> adenosine receptors, while the presence of a chlorine atom in the 2 position favoured the interaction with the A<sub>2A</sub> subtype. These results demonstrated that, although the synthesized compounds were found to be quite inactive at the human A<sub>2B</sub> subtype, adenine is a useful template for further development of simplified adenosine receptor antagonists with distinct receptor selectivity profiles, opening up new chances to design structurally simplified A<sub>1</sub> and A<sub>3</sub> adenosine receptor antagonists.</p>
    </sec>
    <sec id="Sec5">
      <title>Experimental section</title>
      <sec id="Sec6">
        <title>Chemistry</title>
        <p><bold>General:</bold> melting points were determined with a B&#xFC;chi apparatus and are uncorrected. <sup>1</sup>H NMR spectra were obtained with Varian VXR 300&#xA0;MHz spectrometer; &#x3B4; in ppm, <italic>J</italic> in Hz. All exchangeable protons were confirmed by addition of D<sub>2</sub>O. Thin layer chromatography (TLC) was carried out on precoated TLC plates with silica gel 60&#xA0;F-254 (Merck). For column chromatography, silica gel 60 (Merck) was used. Elemental analyses were determined on Fisons Instruments Model EA 1108 CHNS-O model analyser and are within &#xB1; 0.4% of theoretical values.</p>
        <sec id="Sec7">
          <title>9-Propyladenine (<bold><italic>5</italic></bold>) <italic>and 7-propyladenine</italic> (<bold><italic>5a</italic></bold>)</title>
          <p>To a solution of adenine (<bold>15</bold>) (0.5&#xA0;g, 3.7&#xA0;mmol) in dry DMF (10&#xA0;ml), under nitrogen, K<sub>2</sub>CO<sub>3</sub> (0.83&#xA0;g, 5.97&#xA0;mmol) and propyliodide (0.433&#xA0;ml, 4.44&#xA0;mmol) were added. The mixture was stirred at RT for 16&#xA0;h, then the solvent was removed under reduced pressure and the crude purified by flash chromatography (CHCl<sub>3</sub>-MeOH 98:2) to afford <bold>5</bold> [<xref ref-type="bibr" rid="CR23">23</xref>] and <bold>5a</bold> (yield 79 and 9%, respectively) as white solids, after crystallization from CH<sub>3</sub>OH.</p>
          <p><bold>5</bold>: m.p. 173&#x2013;175&#xB0;C. <sup>1</sup>H-NMR (DMSO-<italic>d</italic><sub>6</sub>) &#x3B4; 0.85 (t, 3H, <italic>J</italic>&#x2009;=&#x2009;7.4, CH<sub>3</sub>); 1.82 (m, 2H, <italic>CH</italic><sub><italic>2</italic></sub>-CH<sub>3</sub>); 4.11 (t, 2H, <italic>J</italic>&#x2009;=&#x2009;7.0, CH<sub>2</sub>-N); 7.21 (bs, 2H, NH<sub>2</sub>); 8.15 (s, 2H, H-2 and H-8). Anal. Calcd. for C<sub>5</sub>H<sub>5</sub>N<sub>5</sub> (177.2) C, 54.22; H, 6.26; N, 39.52; found: C, 54.54; H, 6.71; N, 39.33.</p>
          <p><bold>5a</bold>: m.p. &gt;250&#xB0;C. <sup>1</sup>H-NMR (DMSO-<italic>d</italic><sub>6</sub>) &#x3B4; 0.86 (t, 3H, <italic>J</italic>&#x2009;=&#x2009;7.3, CH<sub>3</sub>); 1.91 (m, 2H, <italic>CH</italic><sub><italic>2</italic></sub>-CH<sub>3</sub>); 4.26 (t, 2H, <italic>J</italic>&#x2009;=&#x2009;7.0, CH<sub>2</sub>-N); 7.75 (s, 1H, H-2); 7.85 (bs, 2H, NH<sub>2</sub>); 8.34 (s, 1H, H-8). Anal. Calcd. for C<sub>5</sub>H<sub>5</sub>N<sub>5</sub> (177.2) C, 54.22; H, 6.26; N, 39.52; found: C, 54.45; H, 6.45; N, 39.45.</p>
        </sec>
        <sec id="Sec8">
          <title>2,6-Dichloro-9-propyl-9H-purine (<bold><italic>17</italic></bold>) <italic>and 2,6-dichloro-7-propyl-9H-purine</italic> (<bold><italic>17a</italic></bold>)</title>
          <p>To a solution of 2,6-dichloropurine (<bold>16</bold>) (1&#xA0;g, 5.29&#xA0;mmol) in dry DMF (14&#xA0;ml), under nitrogen, K<sub>2</sub>CO<sub>3</sub> (1.18&#xA0;g, 6.61&#xA0;mmol) and propyliodide (0.59&#xA0;ml, 6.08&#xA0;mmol) were added. The mixture was stirred at RT overnight, then the solvent was removed under reduced pressure and the crude purified by flash chromatography (cC<sub>6</sub>H<sub>12</sub>-EtOAc 75:25) to afford <bold>17</bold> and <bold>17a</bold> as white solids (yield 75 and 10%, respectively) [<xref ref-type="bibr" rid="CR24">24</xref>].</p>
          <p><bold>17</bold>: m.p. 58&#x2013;59&#xB0;C; <sup>1</sup>H-NMR (DMSO- <italic>d</italic><sub>6</sub>) &#x3B4; 0.86 (t, 3H, <italic>J</italic>&#x2009;=&#x2009;7.5&#xA0;Hz, CH<sub>2</sub><italic>CH</italic><sub><italic>3</italic></sub>), 1.85 (m, 2H, <italic>CH</italic><sub><italic>2</italic></sub>CH<sub>3</sub>), 4.21 (t, 2H, <italic>J</italic>&#x2009;=&#x2009;7.0&#xA0;Hz, N-CH<sub>2</sub>), 8.76 (s, 1H, H-8). Anal. Calcd. for C<sub>8</sub>H<sub>8</sub>Cl<sub>2</sub>N<sub>4</sub> (231.1) C, 41.58; H, 3.49; N, 24.25. Found: C, 41.85; H, 3.70; N, 24.10.</p>
          <p><bold>17a</bold>: m.p. 103&#x2013;105&#xB0;C; <sup>1</sup>H-NMR (DMSO-<italic>d</italic><sub>6</sub>) &#x3B4; 0.87 (t, 3H, <italic>J</italic>&#x2009;=&#x2009;7.4&#xA0;Hz, CH<sub>2</sub><italic>CH</italic><sub><italic>3</italic></sub>), 1.84 (m, 2H, <italic>CH</italic><sub><italic>2</italic></sub>CH<sub>3</sub>), 4.40 (t, 2H, <italic>J</italic>&#x2009;=&#x2009;7.2&#xA0;Hz, N-CH<sub>2</sub>), 8.89 (s, 1H, H-8). Anal. Calcd. for C<sub>8</sub>H<sub>8</sub>Cl<sub>2</sub>N<sub>4</sub> (231.1) C, 41.58; H, 3.49; N, 24.25. Found: C, 41.75; H, 3.55; N, 24.19.</p>
        </sec>
        <sec id="Sec9">
          <title>2-Chloro-9-propyladenine (<bold><italic>6</italic></bold>)</title>
          <p>Liquid ammonia (5&#xA0;ml) and compound <bold>17</bold> (0.46&#xA0;g, 1.97&#xA0;mmol) were poured into a sealed tube and the resulting mixture was stirred at RT overnight. Ammonia was evaporated and the crude purified by flash chromatography (CHCl<sub>3</sub>-MeOH 99:1) to give <bold>6</bold> [<xref ref-type="bibr" rid="CR24">24</xref>] as a white solid (yield 75%) m.p. 224&#x2013;226&#xB0;C. <sup>1</sup>H-NMR (DMSO-<italic>d</italic><sub><italic>6</italic></sub>) &#x3B4; 0.84 (t, 3H, <italic>J</italic>&#x2009;=&#x2009;7.3&#xA0;Hz, CH<sub>2</sub><italic>CH</italic><sub><italic>3</italic></sub>), 1.79 (m, 2H, <italic>CH</italic><sub><italic>2</italic></sub>CH<sub>3</sub>), 4.05 (t, 2H, <italic>J</italic>&#x2009;=&#x2009;7.2&#xA0;Hz, N-CH<sub>2</sub>), 7.72 (s, 2H, NH<sub>2</sub>), 8.15 (s, 1H, H-8). Anal. Calcd. for C<sub>8</sub>H<sub>10</sub>ClN<sub>5</sub> (211.7) C, 45.40; H, 4.76; N, 33.09. Found: C, 45.75; H, 4.80; N, 32.87.</p>
        </sec>
        <sec id="Sec10">
          <title>General procedure for the preparation of the <italic>N</italic><sup>6</sup>-acylaminoadenine (<bold><italic>7</italic></bold>&#x2013;<bold><italic>14</italic></bold>)</title>
          <p>A solution in dry THF (4&#xA0;ml) of the appropriate acid (<bold>18&#x2013;22</bold>) (0.46&#xA0;mmol) and carbonyldiimidazole (83&#xA0;mg, 0.51&#xA0;mmol) was poured at reflux under nitrogen for 1&#xA0;h. Then the amino compound <bold>5</bold> or <bold>6</bold> (0.46&#xA0;mmol) was added and the resulting mixture was refluxed overnight. The solvent was removed under reduced pressure and the crude purified by flash chromatography to afford the desired final compounds <bold>7&#x2013;14</bold>.</p>
        </sec>
        <sec id="Sec11">
          <title>6-[(4-Bromophenyl)acetyl]amino-9-propyladenine (<bold><italic>7</italic></bold>)</title>
          <p>Eluent for chromatography CHCl<sub>3</sub>-MeOH 95:5; yield 59%, white solid; m.p. 149&#x2013;151&#xB0;C (dec.); <sup>1</sup>H-NMR (DMSO-<italic>d</italic><sub>6</sub>): &#x3B4; 0.83 (t, 3H, <italic>J</italic>&#x2009;=&#x2009;7.2&#xA0;Hz, CH<sub>2</sub><italic>CH</italic><sub><italic>3</italic></sub>), 1.84 (m, 2H, <italic>CH</italic><sub><italic>2</italic></sub>CH<sub>3</sub>), 3.89 (s, 2H, CH<sub>2</sub>-CO), 4.19 (t, 2H, <italic>J</italic>&#x2009;=&#x2009;7.1&#xA0;Hz, N-CH<sub>2</sub>), 7.30 (d, 2H, <italic>J</italic>&#x2009;=&#x2009;8.4&#xA0;Hz, H-Ph), 7.51 (d, 2H, <italic>J</italic>&#x2009;=&#x2009;8.4&#xA0;Hz, H-Ph), 8.47 (s, 1H, H-8), 8.62 (s, 1H, H-2), 10.91 (s, 1H, NH). Anal. Calcd. for C<sub>16</sub>H<sub>16</sub>BrN<sub>5</sub>O (374.2) C, 51.35; H, 4.31; N, 18.71. Found: C, 51.65; H, 4.80; N, 18.50.</p>
        </sec>
        <sec id="Sec12">
          <title>6-[(4-Bromophenyl)acetyl]amino-2-chloro-9-propyladenine (<bold><italic>8</italic></bold>)</title>
          <p>Eluent for chromatography CHCl<sub>3</sub>-cC<sub>6</sub>H<sub>12</sub> 80:20; yield 26%, white solid; m.p. 164&#x2013;166&#xB0;C; <sup>1</sup>H-NMR (DMSO-<italic>d</italic><sub>6</sub>): &#x3B4; 0.84 (t, 3H, <italic>J</italic>&#x2009;=&#x2009;7.5&#xA0;Hz, CH<sub>2</sub><italic>CH</italic><sub><italic>3</italic></sub>), 1.83 (m, 2H, <italic>CH</italic><sub><italic>2</italic></sub>CH<sub>3</sub>), 3.88 (s, 2H, CH<sub>2</sub>-CO), 4.15 (t, 2H, <italic>J</italic>&#x2009;=&#x2009;6.9&#xA0;Hz, N-CH<sub>2</sub>), 7.30 (d, 2H, <italic>J</italic>&#x2009;=&#x2009;8.4&#xA0;Hz, H-Ph), 7.53 (d, 2H, <italic>J</italic>&#x2009;=&#x2009;8.4&#xA0;Hz, H-Ph), 8.50 (s, 1H, H-8), 11.25 (s, 1H, NH). Anal. Calcd. for C<sub>16</sub>H<sub>15</sub>BrClN<sub>5</sub>O (408.7) C, 47.02; H, 3.70; N, 17.14. Found: C, 47.49; H, 3.83; N, 17.40.</p>
        </sec>
        <sec id="Sec13">
          <title>6-[(4-(4-Bromobenzyloxy)phenyl)acetyl]amino-9-propyladenine (<bold><italic>9</italic></bold>)</title>
          <p>Eluent for chromatography CHCl<sub>3</sub>-MeOH 95:5; yield 58%, white solid; m.p. 154&#x2013;156&#xB0;C; <sup>1</sup>H-NMR (DMSO-<italic>d</italic><sub>6</sub>): &#x3B4; 0.85 (t, 3H, <italic>J</italic>&#x2009;=&#x2009;7.5&#xA0;Hz, CH<sub>2</sub><italic>CH</italic><sub><italic>3</italic></sub>), 1.85 (m, 2H, <italic>CH</italic><sub><italic>2</italic></sub>CH<sub>3</sub>), 3.82 (s, 2H, CH<sub>2</sub>-CO), 4.21 (t, 1H, <italic>J</italic>&#x2009;=&#x2009;7.0&#xA0;Hz, N-CH<sub>2</sub>), 5.07 (s, 2H, CH<sub>2</sub>-O), 6.95 (d, 2H, <italic>J</italic>&#x2009;=&#x2009;8.8&#xA0;Hz, H-Ph), 7.27 (d, 2H, <italic>J</italic>&#x2009;=&#x2009;8.4&#xA0;Hz, H-Ph), 7.40 (d, 2H, <italic>J</italic>&#x2009;=&#x2009;8.4&#xA0;Hz, H-Ph), 7.58 (d, 2H, <italic>J</italic>&#x2009;=&#x2009;8.4&#xA0;Hz, H-Ph), 8.48 (s, 1H, H-8), 8.62 (s, 1H, H-2), 10.81 (s, 1H, NH). Anal. Calcd. for C<sub>23</sub>H<sub>22</sub>BrN<sub>5</sub>O<sub>2</sub> (480.4) C, 57.51; H, 4.62; N, 14.58. Found: C, 57.99; H, 4.66; N, 14.55.</p>
        </sec>
        <sec id="Sec14">
          <title>6-[(4-(4-Bromobenzyloxy)phenyl)acetyl]amino-2-chloro-9-propyladenine (<bold><italic>10</italic></bold>)</title>
          <p>Eluent for chromatography CHCl<sub>3</sub>-cC<sub>6</sub>H<sub>12</sub>-MeOH 50:48:2; yield 14%, white solid; m.p. 176&#x2013;178&#xB0;C; <sup>1</sup>H-NMR (DMSO-<italic>d</italic><sub>6</sub>): &#x3B4; 0.81 (t, 3H, <italic>J</italic>&#x2009;=&#x2009;7.5&#xA0;Hz, CH<sub>2</sub><italic>CH</italic><sub><italic>3</italic></sub>), 1.79 (m, 2H, <italic>CH</italic><sub><italic>2</italic></sub>CH<sub>3</sub>), 3.76 (s, 2H, CH<sub>2</sub>-CO), 4.12 (t, 2H, <italic>J</italic>&#x2009;=&#x2009;7.4&#xA0;Hz, N-CH<sub>2</sub>), 5.03 (s, 2H, CH<sub>2</sub>-O), 6.92 (d, 2H, <italic>J</italic>&#x2009;=&#x2009;8.6&#xA0;Hz, H-Ph), 7.22 (d, 2H, <italic>J</italic>&#x2009;=&#x2009;8.4&#xA0;Hz, H-Ph), 7.36 (d, 2H, <italic>J</italic>&#x2009;=&#x2009;8.4&#xA0;Hz, H-Ph), 7.54 (d, 2H, <italic>J</italic>&#x2009;=&#x2009;8.4&#xA0;Hz, H-Ph), 8.46 (s, 1H, H-8), 11.11 (s, 1H, NH). Anal. Calcd. for C<sub>23</sub>H<sub>21</sub>BrClN<sub>5</sub>O<sub>2</sub> (514.8) C, 53.66; H, 4.11; N, 13.60. Found: C, 53.75; H, 4.25; N, 13.29.</p>
        </sec>
        <sec id="Sec15">
          <title>6-[(4-(4-Methylbenzyloxy)phenyl)acetyl]amino-9-propyladenine (<bold><italic>11</italic></bold>)</title>
          <p>Eluent for chromatography CHCl<sub>3</sub>-cC<sub>6</sub>H<sub>12</sub>-MeOH 70:28:2; yield 35%, white solid; m.p.131&#x2013;132&#xB0;C; <sup>1</sup>H-NMR (DMSO-<italic>d</italic><sub>6</sub>): &#x3B4; 0.83 (t, 3H, <italic>J</italic>&#x2009;=&#x2009;7.3&#xA0;Hz, CH<sub>2</sub><italic>CH</italic><sub><italic>3</italic></sub>), 1.84 (m, 2H, <italic>CH</italic><sub><italic>2</italic></sub>CH<sub>3</sub>), 2.28 (s, 3H, <italic>CH</italic><sub><italic>3</italic></sub>-Ph), 3.80 (s, 2H, CH<sub>2</sub>-CO), 4.20 (t, 2H, <italic>J</italic>&#x2009;=&#x2009;7.1&#xA0;Hz, N-CH<sub>2</sub>), 5.02 (s, 2H, CH<sub>2</sub>-O), 6.93 (d, 2H, <italic>J</italic>&#x2009;=&#x2009;8.4&#xA0;Hz, H-Ph), 7.24 (m, 6H, H-Ph), 8.47 (s, 1H, H-8), 8.62 (s, 1H, H-2), 10.83 (s, 1H, NH). Anal. Calcd. for C<sub>24</sub>H<sub>25</sub>N<sub>5</sub>O<sub>2</sub> (415.5) C, 69.38; H, 6.06; N, 16.86. Found: C, 69.74; H, 6.35; N, 16.54.</p>
        </sec>
        <sec id="Sec16">
          <title>6-[(4-Benzyloxyphenyl)acetyl]amino-9-propyladenine (<bold><italic>12</italic></bold>)</title>
          <p>Eluent for chromatography CHCl<sub>3</sub>-MeOH 97:3; yield 52%, white solid; m.p. 121&#x2013;123&#xB0;C; <sup>1</sup>H-NMR (DMSO-<italic>d</italic><sub>6</sub>): &#x3B4; 0.83(t, 3H, <italic>J</italic>&#x2009;=&#x2009;7.5&#xA0;Hz, CH<sub>2</sub><italic>CH</italic><sub><italic>3</italic></sub>), 1.84 (m, 2H, <italic>CH</italic><sub><italic>2</italic></sub>CH<sub>3</sub>), 3.80 (s, 2H, CH<sub>2</sub>-CO), 4.19 (t, 2H, <italic>J</italic>&#x2009;=&#x2009;7.1&#xA0;Hz, N-CH<sub>2</sub>), 5.07 (s, 2H, CH<sub>2</sub>-O), 6.95 (d, 2H, <italic>J</italic>&#x2009;=&#x2009;8.4&#xA0;Hz, H-Ph), 7.25 (d, 2H, <italic>J</italic>&#x2009;=&#x2009;8.8&#xA0;Hz, H-Ph), 7.37 (m, 5H, H-Ph), 8.47 (s, 1H, H-8), 8.62 (s, 1H, H-2), 10.82 (s, 1H, NH). Anal. Calcd. for C<sub>23</sub>H<sub>23</sub>N<sub>5</sub>O<sub>2</sub> (401.5) C, 68.81; H, 5.77; N, 17.44. Found: C, 68.97; H, 5.89; N, 17.35.</p>
        </sec>
        <sec id="Sec17">
          <title>6-[(4-Benzyloxyphenyl)acetyl]amino-2-chloro-9-propyladenine (<bold><italic>13</italic></bold>)</title>
          <p>Eluent for chromatography CHCl<sub>3</sub>-MeOH 99:1; yield 17%, white solid; m.p. 150&#x2013;152&#xB0;C; <sup>1</sup>H-NMR (DMSO-<italic>d</italic><sub>6</sub>): &#x3B4; 0.84 (t, 3H, <italic>J</italic>&#x2009;=&#x2009;7.3&#xA0;Hz, CH<sub>2</sub><italic>CH</italic><sub><italic>3</italic></sub>), 1.82 (m, 2H, <italic>CH</italic><sub><italic>2</italic></sub>CH<sub>3</sub>), 3.79 (s, 2H, CH<sub>2</sub>-CO), 4.14 (t, 2H, <italic>J</italic>&#x2009;=&#x2009;7.0&#xA0;Hz, N-CH<sub>2</sub>), 5.07 (s, 2H, CH<sub>2</sub>-O), 6.95 (d, 2H, <italic>J</italic>&#x2009;=&#x2009;8.6&#xA0;Hz, H-Ph), 7.25 (d, 2H, <italic>J</italic>&#x2009;=&#x2009;8.4&#xA0;Hz, H-Ph), 7.37 (m, 5H, H-Ph), 8.49 (s, 1H, H-8), 11.16 (s, 1H, NH). Anal. Calcd. for C<sub>23</sub>H<sub>22</sub>ClN<sub>5</sub>O<sub>2</sub> (435.9) C, 63.37; H, 5.09; N, 16.07. Found: C, 63.56; H, 5.14; N, 15.76.</p>
        </sec>
        <sec id="Sec18">
          <title>6-{[(4-Methoxybenzyloxy)phenyl]acetyl}amino-2-chloro-9-propyladenine (<bold><italic>14</italic></bold>)</title>
          <p>Eluent for chromatography CHCl<sub>3</sub>-MeOH 99:1; yield 29%, white solid; m.p. 174&#x2013;176&#xB0;C; <sup>1</sup>H-NMR (DMSO-<italic>d</italic><sub>6</sub>): &#x3B4; 0.84 (t, 3H, <italic>J</italic>&#x2009;=&#x2009;7.4&#xA0;Hz, CH<sub>2</sub><italic>CH</italic><sub><italic>3</italic></sub>), 1.82 (m, 2H, <italic>CH</italic><sub><italic>2</italic></sub>CH<sub>3</sub>), 3.73 (s, 3H, CH<sub>3</sub>-O), 3.79 (s, 3H, CH<sub>2</sub>-CO), 4.14 (t, 2H, <italic>J</italic>&#x2009;=&#x2009;7.0&#xA0;Hz, N-CH<sub>2</sub>), 4.98 (s, 2H, CH<sub>2</sub>-O), 6.92 (d, 2H, <italic>J</italic>&#x2009;=&#x2009;8.0&#xA0;Hz, H-Ph), 6.93 (d, 2H, <italic>J</italic>&#x2009;=&#x2009;8.4&#xA0;Hz, H-Ph), 7.24 (d, 2H, <italic>J</italic>&#x2009;=&#x2009;8.4&#xA0;Hz, H-Ph), 7.35 (d, 2H, <italic>J</italic>&#x2009;=&#x2009;8.4&#xA0;Hz, H-Ph), 8.49 (s, 1H, H-8), 11.15 (s, 1H, NH). Anal. Calcd. for C<sub>24</sub>H<sub>24</sub>ClN<sub>5</sub>O<sub>3</sub> (465.9) C, 61.87; H, 5.19; N, 15.03. Found: C, 61.99; H, 5.33; N, 14.91.</p>
        </sec>
      </sec>
      <sec id="Sec19">
        <title>Biology</title>
        <p>All pharmacological methods followed the procedures as described earlier [<xref ref-type="bibr" rid="CR26">26</xref>]. In brief, membranes for radioligand binding were prepared from CHO cells stably transfected with human adenosine receptor subtypes in a two-step procedure. In a first low-speed step (1,000&#xA0;<italic>g</italic>) cell fragments and nuclei were removed. The crude membrane fraction was sedimented from the supernatant at 100,000&#xA0;<italic>g</italic>. The membrane pellet was resuspended in the buffer used for the respective binding experiments, frozen in liquid nitrogen and stored at &#x2212;80&#xB0;C. For the measurement of adenylyl cyclase activity only one high speed centrifugation of the homogenate was used. The resulting crude membrane pellet was resuspended in 50&#xA0;mM Tris/HCl, pH 7.4 and immediately used for the cyclase assay.</p>
        <p>For radioligand binding at A<sub>1</sub> adenosine receptors 1&#xA0;nM [<sup>3</sup>H]CCPA was used, whereas 30 and 10&#xA0;nM [<sup>3</sup>H]NECA were used for A<sub>2A</sub> and A<sub>3</sub> receptors, respectively. Non-specific binding of [<sup>3</sup>H]CCPA was determined in the presence of 1&#xA0;mM theophylline; in the case of [<sup>3</sup>H]NECA 100&#xA0;pM R-PIA was used. K<sub>i</sub> values from competition experiments were calculated with the program SCTFIT [<xref ref-type="bibr" rid="CR33">33</xref>]. At A<sub>2B</sub> adenosine receptors inhibition of NECA-stimulated adenylyl cyclase activity was used as a measurement of potency of the new compounds. IC<sub>50</sub> values from these experiments were converted to K<sub>i</sub> values with the Cheng and Prusoff equation [<xref ref-type="bibr" rid="CR34">34</xref>].</p>
      </sec>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgements</title>
      <p>The expert technical assistance of Ms. Sonja Kachler is gratefully acknowledged. This work was supported by Fondo di Ricerca di Ateneo (University of Camerino) and by grants from the Italian Ministry of Research: FIRB 2003, and PRIN 2005.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <citation citation-type="other">Cristalli G, Volpini R (eds) (2003) Adenosine receptors: medicinal chemistry, pharmacology and therapeutic applications. Curr Top Med Chem 3:355&#x2013;469</citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Robeva</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Woodard</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Ji</surname>
              <given-names>XD</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Bhattacharya</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>HE</given-names>
            </name>
            <name>
              <surname>Rosin</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Linden</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Molecular characterization of recombinant human adenosine receptors</article-title>
          <source>Drug Dev Res</source>
          <year>1996</year>
          <volume>39</volume>
          <fpage>243</fpage>
          <lpage>252</lpage>
          <pub-id pub-id-type="doi">10.1002/(SICI)1098-2299(199611/12)39:3/4&lt;243::AID-DDR3&gt;3.0.CO;2-R</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Robeva AS, Woodard RL, Ji XD, Gao Z, Bhattacharya S, Taylor HE, Rosin DL, Linden J (1996) Molecular characterization of recombinant human adenosine receptors. Drug Dev Res 39:243&#x2013;252 </citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fredholm</surname>
              <given-names>BB</given-names>
            </name>
            <name>
              <surname>IJzerman</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Klotz</surname>
              <given-names>K-N</given-names>
            </name>
            <name>
              <surname>Linden</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors</article-title>
          <source>Pharmacol Rev</source>
          <year>2001</year>
          <volume>53</volume>
          <fpage>527</fpage>
          <lpage>533</lpage>
        </citation>
        <citation citation-type="display-unstructured">Fredholm BB, IJzerman AP, Klotz K-N, Linden J (2001) International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53:527&#x2013;533 <pub-id pub-id-type="pmid">11734617</pub-id></citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jacobson</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
          <article-title>Adenosine receptor agonists</article-title>
          <source>Expert Opin Ther Pat</source>
          <year>2002</year>
          <volume>12</volume>
          <fpage>489</fpage>
          <lpage>501</lpage>
          <pub-id pub-id-type="doi">10.1517/13543776.12.4.489</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Jacobson MJ (2002) Adenosine receptor agonists. Expert Opin Ther Pat 12:489&#x2013;501 </citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Feoktistov</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Biaggioni</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Adenosine A<sub>2B</sub> receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma</article-title>
          <source>J Clin Invest</source>
          <year>1995</year>
          <volume>96</volume>
          <fpage>1979</fpage>
          <lpage>1986</lpage>
        </citation>
        <citation citation-type="display-unstructured">Feoktistov I, Biaggioni I (1995) Adenosine A2B receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma. J Clin Invest 96:1979&#x2013;1986 <pub-id pub-id-type="pmid">7560091</pub-id></citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marquardt</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Walker</surname>
              <given-names>LL</given-names>
            </name>
            <name>
              <surname>Heinemann</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Cloning of two adenosine receptor subtypes from mouse bone marrow-derived mast cells</article-title>
          <source>J Immunol</source>
          <year>1994</year>
          <volume>152</volume>
          <fpage>4508</fpage>
          <lpage>4515</lpage>
        </citation>
        <citation citation-type="display-unstructured">Marquardt DL, Walker LL, Heinemann S (1994) Cloning of two adenosine receptor subtypes from mouse bone marrow-derived mast cells. J Immunol 152:4508&#x2013;4515 <pub-id pub-id-type="pmid">8157966</pub-id></citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boyle</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Sajjadi</surname>
              <given-names>FG</given-names>
            </name>
            <name>
              <surname>Firestein</surname>
              <given-names>GS</given-names>
            </name>
          </person-group>
          <article-title>Inhibition of synoviocyte collagenase gene expression by adenosine receptor stimulation</article-title>
          <source>Arthritis Rheum</source>
          <year>1996</year>
          <volume>39</volume>
          <fpage>923</fpage>
          <lpage>930</lpage>
          <pub-id pub-id-type="doi">10.1002/art.1780390608</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Boyle DL, Sajjadi FG, Firestein GS (1996) Inhibition of synoviocyte collagenase gene expression by adenosine receptor stimulation. Arthritis Rheum 39:923&#x2013;930 <pub-id pub-id-type="pmid">8651985</pub-id></citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fiebich</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Biber</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Guipko</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Berger</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bauer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Calker</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Adenosine A<sub>2B</sub> receptors mediate an increase in interleukin (IL)-6 mRNA and IL-6 protein synthesis in human astroglioma cells</article-title>
          <source>J Neurochem</source>
          <year>1996</year>
          <volume>66</volume>
          <fpage>1426</fpage>
          <lpage>1431</lpage>
        </citation>
        <citation citation-type="display-unstructured">Fiebich BL, Biber K, Guipko K, Berger M, Bauer J, van Calker D (1996) Adenosine A2B receptors mediate an increase in interleukin (IL)-6 mRNA and IL-6 protein synthesis in human astroglioma cells. J Neurochem 66:1426&#x2013;1431 <pub-id pub-id-type="pmid">8627294</pub-id></citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dubey</surname>
              <given-names>RK</given-names>
            </name>
            <name>
              <surname>Gillaspie</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Osaka</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Suzuki</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Jackson</surname>
              <given-names>EK</given-names>
            </name>
          </person-group>
          <article-title>Adenosine inhibits growth of rat aortic smooth muscle cells: possible role of A<sub>2B</sub> receptors</article-title>
          <source>Hypertension</source>
          <year>1996</year>
          <volume>27</volume>
          <fpage>786</fpage>
          <lpage>793</lpage>
        </citation>
        <citation citation-type="display-unstructured">Dubey RK, Gillaspie DG, Osaka K, Suzuki F, Jackson EK (1996) Adenosine inhibits growth of rat aortic smooth muscle cells: possible role of A2B receptors. Hypertension 27:786&#x2013;793 <pub-id pub-id-type="pmid">8613241</pub-id></citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Feoktistov</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Biaggioni</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Adenosine A<sub>2B</sub> receptors</article-title>
          <source>Pharmacol Rev</source>
          <year>1997</year>
          <volume>49</volume>
          <fpage>381</fpage>
          <lpage>402</lpage>
        </citation>
        <citation citation-type="display-unstructured">Feoktistov I, Biaggioni I (1997) Adenosine A2B receptors. Pharmacol Rev 49:381&#x2013;402 <pub-id pub-id-type="pmid">9443164</pub-id></citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Feoktistov</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Wells</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>Biaggioni</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Adenosine A<sub>2B</sub> receptors as therapeutic targets</article-title>
          <source>Drug Dev Res</source>
          <year>1998</year>
          <volume>45</volume>
          <fpage>198</fpage>
          <lpage>206</lpage>
          <pub-id pub-id-type="doi">10.1002/(SICI)1098-2299(199811/12)45:3/4&lt;198::AID-DDR17&gt;3.0.CO;2-#</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Feoktistov I, Wells JN, Biaggioni I (1998) Adenosine A2B receptors as therapeutic targets. Drug Dev Res 45:198&#x2013;206 </citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Feoktistov</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Biaggioni</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Pharmacological characterization of adenosine A<sub>2B</sub> receptors</article-title>
          <source>Biochem Pharmacol</source>
          <year>1998</year>
          <volume>55</volume>
          <fpage>627</fpage>
          <lpage>633</lpage>
          <pub-id pub-id-type="doi">10.1016/S0006-2952(97)00512-1</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Feoktistov I, Biaggioni I (1998) Pharmacological characterization of adenosine A2B receptors. Biochem Pharmacol 55:627&#x2013;633 <pub-id pub-id-type="pmid">9515573</pub-id></citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Beukers</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Meurs</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>IJzerman</surname>
              <given-names>AP</given-names>
            </name>
          </person-group>
          <article-title>Structure affinity relationships of adenosine A<sub>2B</sub> receptor ligands</article-title>
          <source>Med Res Rev</source>
          <year>2006</year>
          <volume>26</volume>
          <fpage>667</fpage>
          <lpage>698</lpage>
          <pub-id pub-id-type="doi">10.1002/med.20069</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Beukers MW, Meurs I, IJzerman AP (2006) Structure affinity relationships of adenosine A2B receptor ligands. Med Res Rev 26:667&#x2013;698 <pub-id pub-id-type="pmid">16847822</pub-id></citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>YC</given-names>
            </name>
            <name>
              <surname>Ji</surname>
              <given-names>X-D</given-names>
            </name>
            <name>
              <surname>Melman</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Linden</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Jacobson</surname>
              <given-names>KA</given-names>
            </name>
          </person-group>
          <article-title>Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A<sub>2B</sub> adenosine receptors</article-title>
          <source>J Med Chem</source>
          <year>2000</year>
          <volume>43</volume>
          <fpage>1165</fpage>
          <lpage>1172</lpage>
          <pub-id pub-id-type="doi">10.1021/jm990421v</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kim YC, Ji X-D, Melman N, Linden J, Jacobson KA (2000) Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A2B adenosine receptors. J Med Chem 43:1165&#x2013;1172 <pub-id pub-id-type="pmid">10737749</pub-id></citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kalla</surname>
              <given-names>RV</given-names>
            </name>
            <name>
              <surname>Elzein</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Perry</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Palle</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Varkhedkar</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Gimbe&#xF2;</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Maa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Zang</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Zablocki</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Novel 1,3-disubstituted 8-(1-benzyl-1H-pyrazol-4-yl) xanthines: high affinity and selective A<sub>2B</sub> adenosine receptor antagonists</article-title>
          <source>J Med Chem</source>
          <year>2006</year>
          <volume>49</volume>
          <fpage>3682</fpage>
          <lpage>3692</lpage>
          <pub-id pub-id-type="doi">10.1021/jm051268+</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kalla RV, Elzein E, Perry T, Li X, Palle V, Varkhedkar V, Gimbe&#xF2; A, Maa T, Zang D, Zablocki J (2006) Novel 1,3-disubstituted 8-(1-benzyl-1H-pyrazol-4-yl) xanthines: high affinity and selective A2B adenosine receptor antagonists. J Med Chem 49:3682&#x2013;3692 <pub-id pub-id-type="pmid">16759111</pub-id></citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pastorin</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Ros</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Spalluto</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Deflorian</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Moro</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cacciari</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Baraldi</surname>
              <given-names>PG</given-names>
            </name>
            <name>
              <surname>Gessi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Varani</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Borea</surname>
              <given-names>PA</given-names>
            </name>
          </person-group>
          <article-title>Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor antagonists. Influence of the N5 substituent on the affinity at the human A<sub>3</sub> and A<sub>2B</sub> adenosine receptor subtypes: a molecular modeling investigation</article-title>
          <source>J Med Chem</source>
          <year>2003</year>
          <volume>46</volume>
          <fpage>4287</fpage>
          <lpage>4296</lpage>
          <pub-id pub-id-type="doi">10.1021/jm030852k</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Pastorin G, Da Ros T, Spalluto G, Deflorian F, Moro S, Cacciari B, Baraldi PG, Gessi S, Varani K, Borea PA (2003) Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor antagonists. Influence of the N5 substituent on the affinity at the human A3 and A2B adenosine receptor subtypes: a molecular modeling investigation. J Med Chem 46:4287&#x2013;4296 <pub-id pub-id-type="pmid">13678407</pub-id></citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vidal</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Nueda</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Esteve</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Domenech</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Benito</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Renoso</surname>
              <given-names>RF</given-names>
            </name>
            <name>
              <surname>Pont</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Calbet</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lopez</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Cadavid</surname>
              <given-names>MI</given-names>
            </name>
            <name>
              <surname>Loza</surname>
              <given-names>MI</given-names>
            </name>
            <name>
              <surname>Cardenas</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Godessart</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Beleta</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Warzelow</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Ryder</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Discovery and characterization of 4&#x2019;-(2-furyl)-N-pyridin-3-yl-4,5&#x2019;bipyrimidin-2&#x2019;-amine (LAS38096), a potent and efficacious A<sub>2B</sub> adenosine receptor antagonist</article-title>
          <source>J Med Chem</source>
          <year>2007</year>
          <volume>50</volume>
          <fpage>2732</fpage>
          <lpage>2736</lpage>
          <pub-id pub-id-type="doi">10.1021/jm061333v</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Vidal B, Nueda A, Esteve C, Domenech T, Benito S, Renoso RF, Pont M, Calbet M, Lopez R, Cadavid MI, Loza MI, Cardenas A, Godessart N, Beleta J, Warzelow G, Ryder H (2007) Discovery and characterization of 4&#x2019;-(2-furyl)-N-pyridin-3-yl-4,5&#x2019;bipyrimidin-2&#x2019;-amine (LAS38096), a potent and efficacious A2B adenosine receptor antagonist. J Med Chem 50:2732&#x2013;2736 <pub-id pub-id-type="pmid">17469811</pub-id></citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cristalli</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Camaioni</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Costanzi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Vittori</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Volpini</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Klotz</surname>
              <given-names>KN</given-names>
            </name>
          </person-group>
          <article-title>Characterization of potent ligands at human recombinant adenosine receptors</article-title>
          <source>Drug Dev Res</source>
          <year>1998</year>
          <volume>45</volume>
          <fpage>176</fpage>
          <lpage>181</lpage>
          <pub-id pub-id-type="doi">10.1002/(SICI)1098-2299(199811/12)45:3/4&lt;176::AID-DDR14&gt;3.0.CO;2-G</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Cristalli G, Camaioni E, Costanzi S, Vittori S, Volpini R, Klotz KN (1998) Characterization of potent ligands at human recombinant adenosine receptors. Drug Dev Res 45:176&#x2013;181 </citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Camaioni</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Costanzi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Vittori</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Volpini</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Klotz</surname>
              <given-names>KN</given-names>
            </name>
            <name>
              <surname>Cristalli</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>New substituted 9-alkylpurines as adenosine receptor ligands</article-title>
          <source>Bioorg Med Chem</source>
          <year>1998</year>
          <volume>6</volume>
          <fpage>523</fpage>
          <lpage>533</lpage>
          <pub-id pub-id-type="doi">10.1016/S0968-0896(98)00007-8</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Camaioni E, Costanzi S, Vittori S, Volpini R, Klotz KN, Cristalli G (1998) New substituted 9-alkylpurines as adenosine receptor ligands. Bioorg Med Chem 6:523&#x2013;533 <pub-id pub-id-type="pmid">9629466</pub-id></citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Klotz</surname>
              <given-names>KN</given-names>
            </name>
            <name>
              <surname>Kachler</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lambertucci</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Vittori</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Volpini</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Cristalli</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>9-Ethyladenine derivatives as adenosine receptor antagonists: 2- and 8-substitution results in distinct selectivities</article-title>
          <source>Naunyn Schmiedebergs Arch Pharmacol</source>
          <year>2003</year>
          <volume>367</volume>
          <fpage>629</fpage>
          <lpage>634</lpage>
          <pub-id pub-id-type="doi">10.1007/s00210-003-0749-9</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Klotz KN, Kachler S, Lambertucci C, Vittori S, Volpini R, Cristalli G (2003) 9-Ethyladenine derivatives as adenosine receptor antagonists: 2- and 8-substitution results in distinct selectivities. Naunyn Schmiedeberg&#x2019;s Arch Pharmacol 367:629&#x2013;634 <pub-id pub-id-type="pmid">12734636</pub-id></citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Volpini</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Costanzi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Vittori</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cristalli</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Klotz</surname>
              <given-names>K-N</given-names>
            </name>
          </person-group>
          <article-title>Medicinal chemistry and pharmacology of A<sub>2B</sub> adenosine receptors</article-title>
          <source>Curr Top Med Chem</source>
          <year>2003</year>
          <volume>3</volume>
          <fpage>427</fpage>
          <lpage>443</lpage>
          <pub-id pub-id-type="doi">10.2174/1568026033392264</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Volpini R, Costanzi S, Vittori S, Cristalli G, Klotz K-N (2003) Medicinal chemistry and pharmacology of A2B adenosine receptors. Curr Top Med Chem 3:427&#x2013;443 <pub-id pub-id-type="pmid">12570760</pub-id></citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Volpini</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Costanzi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lambertucci</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Vittori</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Martini</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Trincavelli</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Klotz</surname>
              <given-names>K-N</given-names>
            </name>
            <name>
              <surname>Cristalli</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>2- And 8-alkynyl-9-ethyladenines: synthesis and biological activity at human and rat adenosine receptors</article-title>
          <source>Purinergic Signalling</source>
          <year>2005</year>
          <volume>1</volume>
          <fpage>173</fpage>
          <lpage>181</lpage>
          <pub-id pub-id-type="doi">10.1007/s11302-005-6216-y</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Volpini R, Costanzi S, Lambertucci C, Vittori S, Martini C, Trincavelli ML, Klotz K-N, Cristalli G (2005) 2- And 8-alkynyl-9-ethyladenines: synthesis and biological activity at human and rat adenosine receptors. Purinergic Signalling 1:173&#x2013;181 </citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Fan</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Vu</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hong</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Brazidec</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Shi</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Biamonte</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Busch</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Lough</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Grecko</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ran</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Sensintaffar</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Camal</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lundgren</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Burrows</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Mansfield</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Timony</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Ulm</surname>
              <given-names>EH</given-names>
            </name>
            <name>
              <surname>Kasibhatla</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Boehm</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>7&#x2019;-Substituted benzothiazolothio- and pyridinothiazolothio-purines as potent heat shock protein 90 inhibitors</article-title>
          <source>J Med Chem</source>
          <year>2006</year>
          <volume>49</volume>
          <fpage>5352</fpage>
          <lpage>5362</lpage>
          <pub-id pub-id-type="doi">10.1021/jm051146h</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Zhang L, Fan J, Vu K, Hong K, Le Brazidec JY, Shi J, Biamonte M, Busch DJ, Lough RE, Grecko R, Ran Y, Sensintaffar JL, Camal A, Lundgren K, Burrows FJ, Mansfield R, Timony GA, Ulm EH, Kasibhatla SR, Boehm M (2006) 7&#x2019;-Substituted benzothiazolothio- and pyridinothiazolothio-purines as potent heat shock protein 90 inhibitors. J Med Chem 49:5352&#x2013;5362 <pub-id pub-id-type="pmid">16913725</pub-id></citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maruyama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kozai</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sasaki</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Methods for the synthesis of uric acid derivatives</article-title>
          <source>Nucleosides Nucleotides Nucleic Acids</source>
          <year>1998</year>
          <volume>19</volume>
          <fpage>1193</fpage>
          <lpage>1203</lpage>
        </citation>
        <citation citation-type="display-unstructured">Maruyama T, Kozai S, Sasaki F (1998) Methods for the synthesis of uric acid derivatives. Nucleosides Nucleotides Nucleic Acids 19:1193&#x2013;1203 <pub-id pub-id-type="pmid">10999257</pub-id></citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <citation citation-type="other">Karaneswsky C, Thomson D, Michellys A, Ruppar P, Chen JH (2005) Preparation of benzoic acid phenylacetic derivatives as HNT&#x2212;4&#xB0; modulators. PCT Int. Appl. WO2005009104200-40716</citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Klotz</surname>
              <given-names>KN</given-names>
            </name>
            <name>
              <surname>Hessling</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hegler</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Owman</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kull</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Fredholm</surname>
              <given-names>BB</given-names>
            </name>
            <name>
              <surname>Lohse</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
          <article-title>Comparative pharmacology of human adenosine receptor subtypes&#x2014;characterization of stably transfected receptors in CHO cells</article-title>
          <source>Naunyn Schmiedebergs Arch Pharmacol</source>
          <year>1998</year>
          <volume>357</volume>
          <fpage>1</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.1007/PL00005131</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Klotz KN, Hessling J, Hegler J, Owman C, Kull B, Fredholm BB, Lohse MJ (1998) Comparative pharmacology of human adenosine receptor subtypes&#x2014;characterization of stably transfected receptors in CHO cells. Naunyn Schmiedeberg&#x2019;s Arch Pharmacol 357:1&#x2013;9 <pub-id pub-id-type="pmid">9459566</pub-id></citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baraldi</surname>
              <given-names>PG</given-names>
            </name>
            <name>
              <surname>Cacciari</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Pineda de las Infantas</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Romagnoli</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Spalluto</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Volpini</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Costanzi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Vittori</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cristalli</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Melman</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Jacobson</surname>
              <given-names>KA</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and biological activity of a new series of <italic>N</italic><sup><italic>6</italic></sup>-arylcarbamoyl-,2-(ar)alkynyl-<italic>N</italic><sup><italic>6</italic></sup>-arylcarbamoyl- and <italic>N</italic><sup><italic>6</italic></sup>-carboxamido-adenosine-5&#x2019;-uronamides as A<sub>3</sub> adenosine receptor agonists</article-title>
          <source>J Med Chem</source>
          <year>1998</year>
          <volume>41</volume>
          <fpage>3174</fpage>
          <lpage>3185</lpage>
          <pub-id pub-id-type="doi">10.1021/jm980147p</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Baraldi PG, Cacciari B, Pineda de las Infantas MJ, Romagnoli R, Spalluto G, Volpini R, Costanzi S, Vittori S, Cristalli G, Melman N, Park K, Jacobson KA (1998) Synthesis and biological activity of a new series of N6-arylcarbamoyl-,2-(ar)alkynyl-N6-arylcarbamoyl- and N6-carboxamido-adenosine-5&#x2019;-uronamides as A3 adenosine receptor agonists. J Med Chem 41:3174&#x2013;3185 <pub-id pub-id-type="pmid">9703463</pub-id></citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Volpini</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Camaioni</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Costanzi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Vittori</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Klotz</surname>
              <given-names>K-N</given-names>
            </name>
            <name>
              <surname>Cristalli</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Synthesis of di- and tri-substituted adenosine derivatives and their affinities at human adenosine receptor subtypes</article-title>
          <source>Nucleosides Nucleotides</source>
          <year>1999</year>
          <volume>18</volume>
          <fpage>2511</fpage>
          <lpage>2520</lpage>
          <pub-id pub-id-type="doi">10.1080/07328319908044623</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Volpini R, Camaioni E, Costanzi S, Vittori S, Klotz K-N, Cristalli G (1999) Synthesis of di- and tri-substituted adenosine derivatives and their affinities at human adenosine receptor subtypes. Nucleosides Nucleotides 18:2511&#x2013;2520 <pub-id pub-id-type="pmid">10639752</pub-id></citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Volpini</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Costanzi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lambertucci</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Taffi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Vittori</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Klotz</surname>
              <given-names>KN</given-names>
            </name>
            <name>
              <surname>Cristalli</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title><italic>N</italic><sup><italic>6</italic></sup>-Alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A<sub>3</sub> receptor and a starting point for searching A<sub>2B</sub> ligands</article-title>
          <source>J Med Chem</source>
          <year>2002</year>
          <volume>45</volume>
          <fpage>3271</fpage>
          <lpage>3279</lpage>
          <pub-id pub-id-type="doi">10.1021/jm0109762</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Volpini R, Costanzi S, Lambertucci C, Taffi S, Vittori S, Klotz KN, Cristalli G (2002) N6-Alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A3 receptor and a starting point for searching A2B ligands. J Med Chem 45:3271&#x2013;3279 <pub-id pub-id-type="pmid">12109910</pub-id></citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cristalli</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lambertucci</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Taffi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Vittori</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Volpini</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Medicinal chemistry of adenosine A<sub>2A</sub> receptor agonists</article-title>
          <source>Curr Top Med Chem</source>
          <year>2003</year>
          <volume>3</volume>
          <fpage>387</fpage>
          <lpage>401</lpage>
          <pub-id pub-id-type="doi">10.2174/1568026033392282</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Cristalli G, Lambertucci C, Taffi S, Vittori S, Volpini R (2003) Medicinal chemistry of adenosine A2A receptor agonists. Curr Top Med Chem 3:387&#x2013;401 <pub-id pub-id-type="pmid">12570757</pub-id></citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Volpini</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ben</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Lambertucci</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Taffi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Vittori</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Klotz</surname>
              <given-names>KN</given-names>
            </name>
            <name>
              <surname>Cristalli</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title><italic>N</italic><sup><italic>6</italic></sup>-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A<sub>3</sub> adenosine receptor</article-title>
          <source>J Med Chem</source>
          <year>2007</year>
          <volume>50</volume>
          <fpage>1222</fpage>
          <lpage>1230</lpage>
          <pub-id pub-id-type="doi">10.1021/jm060963u</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Volpini R, Dal Ben D, Lambertucci C, Taffi S, Vittori S, Klotz KN, Cristalli G (2007) N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem 50:1222&#x2013;1230 <pub-id pub-id-type="pmid">17309246</pub-id></citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cristalli</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Cacciari</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Ben</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Lambertucci</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Moro</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Spalluto</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Volpini</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Medicinal chemistry of adenosine A<sub>2A</sub> receptor agonists</article-title>
          <source>Chem Med Chem</source>
          <year>2007</year>
          <volume>2</volume>
          <fpage>260</fpage>
          <lpage>281</lpage>
        </citation>
        <citation citation-type="display-unstructured">Cristalli G, Cacciari B, Dal Ben D, Lambertucci C, Moro S, Spalluto G, Volpini R (2007) Medicinal chemistry of adenosine A2A receptor agonists. Chem Med Chem 2:260&#x2013;281 <pub-id pub-id-type="pmid">17177231</pub-id></citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lean</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hancock</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Lefkowitz</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
          <article-title>Validation and statistical analysis of a computer modeling method for quantitative analysis of radioligand binding data for mixtures of pharmacological receptor subtypes</article-title>
          <source>Mol Pharmacol</source>
          <year>1982</year>
          <volume>21</volume>
          <fpage>5</fpage>
          <lpage>16</lpage>
        </citation>
        <citation citation-type="display-unstructured">De Lean A, Hancock AA, Lefkowitz RJ (1982) Validation and statistical analysis of a computer modeling method for quantitative analysis of radioligand binding data for mixtures of pharmacological receptor subtypes. Mol Pharmacol 21:5&#x2013;16 <pub-id pub-id-type="pmid">6982395</pub-id></citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cheng</surname>
              <given-names>YC</given-names>
            </name>
            <name>
              <surname>Prusoff</surname>
              <given-names>WH</given-names>
            </name>
          </person-group>
          <article-title>Relationship between the inhibition constant (K<sub>i</sub>) and the concentration of inhibitor which causes 50 per cent inhibition (I<sub>50</sub>) of an enzymatic reaction</article-title>
          <source>Biochem Pharmacol</source>
          <year>1973</year>
          <volume>22</volume>
          <fpage>3099</fpage>
          <lpage>3108</lpage>
          <pub-id pub-id-type="doi">10.1016/0006-2952(73)90196-2</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Cheng YC, Prusoff WH (1973) Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099&#x2013;3108 <pub-id pub-id-type="pmid">4202581</pub-id></citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>